Shared on06 Aug 25Fair value Increased 8.71%
AlzChem Group's higher consensus price target reflects improved profitability and a lower forward P/E, indicating stronger earnings expectations and valuation support, with fair value raised from €124.40 to €135.24. What's in the News AlzChem Group AG confirmed full year 2025 guidance, expecting approximately 5% organic sales growth to around EUR 580 million.
Shared on29 Jul 25Fair value Increased 24%
The significant upward revision in AlzChem Group’s price target is underpinned by improved consensus forecasts for both revenue growth and net profit margin, resulting in a new fair value estimate of €124.40. What's in the News AlzChem Group AG confirmed 2025 earnings guidance, expecting sales to reach approximately EUR 580 million.
Shared on01 May 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Decreased 14%
AnalystConsensusTarget has decreased revenue growth from 9.2% to 7.7%.
Shared on26 Mar 25Fair value Increased 15%
AnalystConsensusTarget has increased revenue growth from 7.7% to 9.2%, increased profit margin from 11.6% to 12.8% and increased shares outstanding growth rate from -0.0% to 0.0%.
Shared on19 Mar 25Fair value Increased 8.24%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on13 Mar 25Fair value Increased 25%
AnalystConsensusTarget has increased future PE multiple from 11.2x to 13.9x.